Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
NCT ID: NCT04499755
Last Updated: 2020-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
100 participants
INTERVENTIONAL
2020-06-01
2030-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI
NCT03749252
Efficacy and Safety of Continuous Infusion of Ketamine in Pediatric Intensive Care Unit (KISS Study)
NCT04427605
A Comparison Between Oral Melatonin With Nasal Sevoflurane Versus Oral Chloral Hydrate With Nasal Sevoflurane in Sedation of Children Undergoing Brain MRI
NCT06606899
Citicoline as Neuroprotector in Preterm
NCT03966170
Ondansetron for Pediatric Mild Traumatic Brain Injury
NCT01815125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nucleo CMP forte
Nucleo CMP forte twice daily for 6 weeks with supportive treatment.
Nucleo CMP Forte
Nucleo CMP Forte twice daily for 6 weeks
Supportive treatment
Supportive treatment only.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nucleo CMP Forte
Nucleo CMP Forte twice daily for 6 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sherief Abd-Elsalam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abeer Salamah, Lecturer
Role: PRINCIPAL_INVESTIGATOR
Pediatrics department - Kafr-Elsheikh University
Mohamed Elbahnasawy, lecturer
Role: PRINCIPAL_INVESTIGATOR
Emergency Department- Tanta University.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sherief Abd-Elsalam
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KFS protocol
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.